Q-omics provides the consensus-scored CYP2C59P profile across patient tissues and cancer cell-line models. CYP2C59P expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in HNSC. Additionally, CYP2C59P RNA expression shows 5,727 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, and STAD as cancer lineages where CYP2C59P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.